| Symbol | MBIO |
|---|---|
| Name | MUSTANG BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 377 PLANTATION STREET, WORCESTER, Massachusetts, 01605, United States |
| Telephone | +1 781 652-4500 |
| Fax | — |
| — | |
| Website | https://www.mustangbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001680048 |
| Description | Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Additional info from NASDAQ: |
Director Litchman Manuel MD 🔴 sold 19 shares of MUSTANG BIO, INC. (MBIO) at $0.75 Transaction Date: Apr 24, 2026 | Filing ID: 049430
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNew Form SCHEDULE 13D/A - MUSTANG BIO, INC. Filed: 2026-01-05 AccNo: 0001104659-26-000690 Size: 14 KB
Read moreDirector Herskowitz Neil 🔴 sold 247 shares of MUSTANG BIO, INC. (MBIO) at $0.96 Transaction Date: Dec 30, 2025 | Filing ID: 125233
Read moreDirector Chill Adam J. 🔴 sold 4 shares of MUSTANG BIO, INC. (MBIO) at $0.95 Transaction Date: Dec 30, 2025 | Filing ID: 125232
Read moreDirector Jin David 🟢 acquired 247 shares of MUSTANG BIO, INC. (MBIO) at $0.96 Transaction Date: Dec 30, 2025 | Filing ID: 125227
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05360238 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Re… | Phase1 | Follicular B-cell Non-Hodgkin's Lymphoma | Terminated | 2022-05-24 | 2024-04-12 | ClinicalTrials.gov |
| NCT05645744 | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR… | — | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Terminated | 2021-09-29 | 2024-04-12 | ClinicalTrials.gov |
| NCT04109482 | Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. | Phase1 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Terminated | 2020-02-17 | 2023-05-17 | ClinicalTrials.gov |
| NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autol… | Phase1 | Recurrent B-Cell Non-Hodgkin Lymphoma | Active_Not_Recruiting | 2017-12-05 | 2039-03-01 | ClinicalTrials.gov |
| NCT03194828 | Real-time Glaucoma Medication Adherence | Na | Glaucoma | Terminated | 2017-05-08 | 2018-07-15 | ClinicalTrials.gov |
| NCT02159495 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Re… | Phase1 | Adult Acute Myeloid Leukemia in Remission | Active_Not_Recruiting | 2015-12-15 | 2026-08-06 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Fludarabine Phosphate | Other | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Leukapheresis | Other | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Cyclophosphamide | Other | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Chimeric Antigen Receptor T-Cell Therapy | Drug | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Medication monitoring only | Drug | Approved | Glaucoma | TERMINATED | NCT03194828 |
| Medication reminder | Drug | Approved | Glaucoma | TERMINATED | NCT03194828 |
| Medication monitoring only | Drug | Approved | Glaucoma | TERMINATED | NCT03194828 |
| Medication reminder | Drug | Approved | Glaucoma | TERMINATED | NCT03194828 |
| Prior MB-106 CAR-T cell investigational product. | Other | Preclinical | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | TERMINATED | NCT05645744 |
| Prior MB-102 CAR-T cell investigational product. | Other | Preclinical | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | TERMINATED | NCT05645744 |
| MB-106 | Other | Phase PHASE1 | Follicular B-cell Non-Hodgkin's Lymphoma | TERMINATED | NCT05360238 |
| Cyclophosphamide | Other | Phase PHASE1 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | TERMINATED | NCT04109482 |
| Fludarabine | Other | Phase PHASE1 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | TERMINATED | NCT04109482 |
| MB-102 | Other | Phase PHASE1 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | TERMINATED | NCT04109482 |
| Fludarabine Phosphate | Other | Phase PHASE1 | Adult Acute Myeloid Leukemia in Remission | ACTIVE_NOT_RECRUITING | NCT02159495 |
| Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes | Other | Phase PHASE1 | Adult Acute Myeloid Leukemia in Remission | ACTIVE_NOT_RECRUITING | NCT02159495 |
| laboratory biomarker analysis | Other | Phase PHASE1 | Adult Acute Myeloid Leukemia in Remission | ACTIVE_NOT_RECRUITING | NCT02159495 |
| Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes | Other | Phase PHASE1 | Adult Acute Myeloid Leukemia in Remission | ACTIVE_NOT_RECRUITING | NCT02159495 |
| cyclophosphamide | Other | Phase PHASE1 | Adult Acute Myeloid Leukemia in Remission | ACTIVE_NOT_RECRUITING | NCT02159495 |
| Fludarabine Phosphate | Other | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Leukapheresis | Other | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Cyclophosphamide | Other | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Chimeric Antigen Receptor T-Cell Therapy | Drug | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Prior MB-106 CAR-T cell investigational product. | BIOLOGICAL | Preclinical | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | TERMINATED | NCT05645744 |
| Prior MB-102 CAR-T cell investigational product. | BIOLOGICAL | Preclinical | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | TERMINATED | NCT05645744 |
| MB-106 | BIOLOGICAL | Phase PHASE1 | Follicular B-cell Non-Hodgkin's Lymphoma | TERMINATED | NCT05360238 |
| Fludarabine | DRUG | Phase PHASE1 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | TERMINATED | NCT04109482 |
| MB-102 | BIOLOGICAL | Phase PHASE1 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | TERMINATED | NCT04109482 |
| Leukapheresis | PROCEDURE | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Laboratory Biomarker Analysis | OTHER | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | TERMINATED | NCT04109482 |
| Chimeric Antigen Receptor T-Cell Therapy | BIOLOGICAL | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Fludarabine Phosphate | DRUG | Phase PHASE1 | Recurrent B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03277729 |
| Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes | BIOLOGICAL | Phase PHASE1 | Adult Acute Myeloid Leukemia in Remission | ACTIVE_NOT_RECRUITING | NCT02159495 |
| laboratory biomarker analysis | OTHER | Phase PHASE1 | Adult Acute Myeloid Leukemia in Remission | ACTIVE_NOT_RECRUITING | NCT02159495 |
| Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes | BIOLOGICAL | Phase PHASE1 | Adult Acute Myeloid Leukemia in Remission | ACTIVE_NOT_RECRUITING | NCT02159495 |
| cyclophosphamide | DRUG | Phase PHASE1 | Adult Acute Myeloid Leukemia in Remission | ACTIVE_NOT_RECRUITING | NCT02159495 |